Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MDMX: from bench to bedside.

Jean-Christophe W Marine1, Michael A Dyer, Aart G Jochemsen

  • 1Laboratory For Molecular Cancer Biology, Flanders Interuniversity Institute for Biotechnology (VIB), University of Ghent, B-9052 Ghent, Belgium. chris.marine@dmbr.ugent.be

Journal of Cell Science
|January 26, 2007
PubMed
Summary

The tumor suppressor protein Mdmx negatively regulates p53. Inhibiting Mdmx may activate p53 in tumors, offering a new cancer treatment strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crop-OCT: a Fully Integrated Imageomics Pipeline to Identify Regional and Focal Retinopathy in Murine Models.

bioRxiv : the preprint server for biology·2026
Same author

Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma.

Cell death & disease·2026
Same author

Protocol for retinal stress culture and single-cell analysis.

STAR protocols·2025
Same author

A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies.

Blood advances·2025
Same author

PAX translocations remodel mitochondrial metabolism through altered leucine usage in rhabdomyosarcoma.

Cell·2025
Same author

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.

Nature communications·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The tumor suppressor protein p53 is crucial for preventing cancer.
  • Mdm2 and Mdmx (also known as Mdm4) are key negative regulators of p53.
  • Aberrant Mdmx expression is implicated in various tumor formations.

Purpose of the Study:

  • To investigate the role of Mdmx as a negative regulator of p53.
  • To explore Mdmx as a potential chemotherapeutic target for cancer treatment.

Main Methods:

  • Review of genetic studies and existing evidence on Mdmx function.
  • Analysis of Mdmx amplification and overexpression in tumors.

Main Results:

  • Mdmx physically interacts with p53 and targets it for degradation.
  • Mdmx amplification and/or overexpression are observed in diverse tumors.
  • Mdmx is identified as a specific therapeutic target for retinoblastoma.

Conclusions:

  • Mdmx is a critical negative regulator of p53.
  • Targeting Mdmx presents a promising strategy for activating p53 in wild-type p53 tumors.
  • Development of Mdmx antagonists is warranted for cancer therapy.

Related Experiment Videos